From PsychonautWiki
Jump to: navigation, search

Skull and crossbones darktextred2.png

25C-NBOMe can be fatal at heavy doses (as low as 4mg).[1]

It is strongly discouraged to take large amounts of this substance or to insufflate (snort) it. Please see this section for more details.

Summary sheet: 25C-NBOMe
Chemical Nomenclature
Common names 25C-NBOMe, Cimbi-36, 25C
Substitutive name 2C-C-NBOMe
Systematic name 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 50 - 100 µg
Light 100 - 300 µg
Common 300 - 700 µg
Strong 700 - 1000 µg
Heavy 25C-NBOMe can be fatal at heavy doses.[1]
Total 8 - 10 hours
Onset 0 - 15 minutes
Come up 30 - 90 minutes
Peak 4 - 6 hours
Offset 1 - 4 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

25C-NBOMe (also known as Cimbi-36, 2C-C-NBOMe, and "N-Bomb", although this term is used broadly to refer to the entire 25x-NBOMe family) is a novel psychedelic substance of the phenethylamine class. It produces an array of visually-dominant and stimulating psychedelic effects when administered.

The name 25C-NBOMe, which is short-hand for 2C-C-NBOMe, is a derivative of the phenethylamine psychedelic 2C-C. It was discovered in 2003 by Ralf Heim at the Free University of Berlin,[2] and subsequently investigated by a team at Purdue University led by David Nichols.[3] It has been studied in its radiolabelled form as a potential ligand for mapping the distribution of serotonin-2A receptors in the brain, using positron emission tomography (PET).[4][5]

Users note that compounds of the NBOMe family are not orally active and should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. 25C-NBOMe can also be vaporized and inhaled for more rapid and powerful effects and a shorter duration. However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are both active in the microgram range which highly elevates the risk of overdose.

25C-NBOMe had no history of human use before being sold online as a designer drug in 2010.[citation needed] Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOMe in humans, and it has been associated with many deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.

Blotter paper containing 25C-NBOMe


25C-NBOMe or 2C-C-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-C. 25C-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a chlorine atom attached to carbon R4. It differs from 2C-C structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25C-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.


Further information: Serotonergic psychedelic

25C-NBOMe has efficacy at the 5-HT2A receptor where it acts as a potent partial agonist.[6] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

In comparison to 2C-C, the addition of an NBOMe group to the structure results in a sixteen fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for LSD.[7] In comparison to LSD however it is only a third of the potency.[8]

Subjective effects

The cognitive effects of 25C-NBOMe are commonly described as being notably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for user to report feeling that their thought stream has maintained a normality in style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
We also recommend that you conduct independent research and use harm reduction practices when using this substance.

25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it can be fatal at heavy dosages.[9] 25C-NBOMe overdoses have also been linked to multi-organ failure.[10][11]

It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing.[12][9]

It is strongly recommended that one use harm reduction practices when using this substances.

Tolerance and addiction potential

25C-NBOMe is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25C-NBOMe are built almost immediately after ingestion. After that, it takes about 7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). 25C-NBOMe presents cross-tolerance with all psychedelics, meaning that after the consumption of 25C-NBOMe all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The following lists some known dangerous combinations, but may not include all of them. A combination that appears to be safe in low doses can still increase the risk of injury or death. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume.

Legal status

  • Austria: 25C-NBOMe is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[14]
  • Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[15]
  • China: As of October 2015 25C-NBOMe is a controlled substance in China.[16]
  • Germany: Possession, production and sale is illegal.[17]
  • Israel: The NBOMe series of psychoactives became controlled in Israel in May, 2013.[18]
  • Italy: In Italy 25C-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.[19]
  • Latvia: 25C-NBOMe is a Schedule I controlled substance.[20]
  • New Zealand 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.[21]
  • Russia: Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.[22][23]
  • Sweden: 25C-NBOMe is classed as Schedule I.[24]
  • United Kingdom: 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[25]
  • United States: Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.[26]

See also

External links



  1. 1.0 1.1 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  2. Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.
  3. Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.
  4. https://www.ncbi.nlm.nih.gov/pubmed/21174090
  5. http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V
  6. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24397362
  7. 25C-NBOMe--new potent hallucinogenic substance identified on the drug market (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/22989597
  8. http://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_dose.shtml
  9. 9.0 9.1 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid - https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  10. Fatal intoxication with the new designer drug 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26324189
  11. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
  12. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
  13. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  14. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  15. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  16. 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html
  17. BtMG Anlage I | https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html
  18. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
  19. Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
  20. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  21. ‘Legal high’ DIME not so legal | http://www.sciencemediacentre.co.nz/2012/03/13/legal-high-dime-not-so-legal/
  22. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
  23. Постановление Правительства Российской Федерации от 6 октября 2011 г. N 822 г. Москва | http://www.rg.ru/2011/10/19/narko-dok.html
  24. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
  25. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
  26. DEA proposed rules | http://www.gpo.gov/fdsys/pkg/FR-2013-10-10/pdf/2013-24432.pdf